Sai Parenterals share price
NSE: SAIPARENTBSE: 544742Pharmaceuticals & BiotechnologySmall Cap
Sai Parenterals Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2026 · Issue price ₹392
Last close ₹478.25up ₹22.60 (4.96%)BSE ₹478.60
Share price at the NSE close on 27 Oct 2026. Previous close ₹455.65.
27 Oct: open ₹464.70, high ₹481.50, low ₹460.05
Range of traded prices from listing on 2 Apr 2026 to 27 Oct 2026
₹400.00Low, 2 Apr 2026₹706.00High, 2 Jul 2026
- Next results date: the board meets on 1 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹2,113 Cr1,118th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No full year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.31
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in Apr 2026
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.65
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,07,58852.2% delivered
Results
Consolidated; ₹ crore.Sai Parenterals quarterly results
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹179 Crdown 9.73%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹7.92 Crdown 39.79%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 4.4%
Revenue by quarter
Peak revenue ₹198 Cr, quarter to Mar 2026; lowest ₹96 Cr, quarter to Dec 2025
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in 1 of the 3 quarters shown
| ₹ crore | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Revenue | 96 | 198 | 179 |
| Net profit | −7 | 13 | 8 |
| Net margin | −6.9% | 6.6% | 4.4% |
Consolidated. The 3 quarters from Dec 2025, the first on record. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026
- Revenue
- ₹381 Cr
- Net profit
- ₹14 Cr
- Net margin
- 3.7%
| ₹ crore | Mar 2026 |
|---|---|
| Revenue | 381 |
| Net profit | 14 |
| Net margin | 3.7% |
Consolidated. Years to March. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, pharmaceutical, which carries all its revenue.
Mutual fund holdings
5 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before.
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 2
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 1
| Fund | |||
|---|---|---|---|
 Bandhan Healthcare FundBandhan Mutual Fund | 70,830 | 1.15% | ₹3.75 Cr |
| Bandhan Midcap FundBandhan Mutual Fund | 52,115 | 0.11% | ₹2.76 Cr |
| Bandhan Large & Mid Cap FundBandhan Mutual Fund | 10,862 | – | ₹0.57 Cr |
 Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 332 | 0.04% | ₹0.02 Cr |
| Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 157 | 0.04% | ₹83,000 |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Sai Parenterals competitors and peers
Pharmaceuticals, 216 listed companies, priced on 27 Oct 2026. The table lists the 8 companies closest to Sai Parenterals in market cap.Healthcare companies
Sai Parenterals is not on the chart: it has no P/E or return on equity today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 HikalHIKAL | 2,489 | – | 2.08 | −5.4% | −153.4% | −2.7% | 3.5% | 0.30% |
 Fredun PharmaceuticalsFREDUN | 2,452 | – | 8.82 | – | – | – | 18.8% | 0.02% |
 Dishman Carbogen AmcisDCAL | 2,316 | 143.30 | 0.35 | +0.2% | −84.5% | 0.3% | 1.4% | 0.00% |
 Beta DrugsBETA | 2,151 | 39.78 | 4.91 | – | – | 16.4% | 14.2% | 0.00% |
 Sakar HealthcareSAKAR | 2,070 | 48.29 | 5.98 | +48.0% | +119.8% | 13.2% | 16.6% | 0.00% |
 Indoco RemediesINDOCO | 2,037 | 63.77 | 1.99 | +10.8% | – | 3.2% | 1.8% | 0.09% |
 Panacea BiotecPANACEABIO | 1,955 | – | 2.34 | +10.3% | −162.0% | −0.9% | −3.6% | 0.00% |
 Syncom Formulations (India)SYNCOMF | 1,937 | 22.65 | 4.67 | +0.4% | +48.6% | 22.6% | 19.5% | 0.49% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Sai Parenterals announcements
Oct 2026
27 Oct · Board meeting
3 Oct · Business
1 Oct · Analysts
Sep 2026
30 Sep · Management
30 Sep · Board meeting
Recent sessions
The 9 trading days to 26 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 26 Oct 2026 | 456.00 | 481.45 | 450.00 | 455.65 | 462.33 | 1,78,868 | 44.2% |
| 23 Oct 2026 | 460.55 | 472.45 | 441.35 | 461.70 | 454.25 | 3,20,040 | 60.5% |
| 22 Oct 2026 | 464.00 | 465.25 | 448.15 | 451.50 | 455.37 | 2,30,332 | 55.7% |
| 21 Oct 2026 | 478.70 | 488.15 | 462.10 | 467.60 | 470.80 | 2,00,138 | 58.1% |
| 19 Oct 2026 | 483.20 | 490.75 | 482.10 | 483.00 | 485.02 | 65,785 | 63.3% |
| 16 Oct 2026 | 483.90 | 492.80 | 480.90 | 487.30 | 487.77 | 53,936 | 55.1% |
| 15 Oct 2026 | 500.00 | 500.00 | 482.00 | 483.90 | 487.63 | 92,729 | 59.5% |
| 14 Oct 2026 | 497.25 | 504.00 | 491.65 | 495.55 | 498.16 | 56,607 | 46.5% |
| 13 Oct 2026 | 504.00 | 504.00 | 492.00 | 498.30 | 496.95 | 62,283 | 53.8% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- SAIPARENT
- BSE code
- 544742
- ISIN
- INE0H9F01037
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.saiparenterals.com
- Registered office
- Plot No. 39, 5TH FLOORLAVANYA ARCADE, JAYABHERI ENCLAVE, 500032, Telangana
- Share registrar
- Bigshare Services Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments